Sort by:
Need a comprehensive medical report on "Acute Myeloid Leukemia (AML)"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
Phase 1
Withdrawn
- Conditions
- Acute Myeloid Leukemia (AML)Minimal Residual Disease
- Interventions
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT03699384
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia
Phase 2
Terminated
- Conditions
- Core Binding Factor Acute Myeloid Leukemia (CBF-AML)
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Niguarda Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT03686345
- Locations
- 🇮🇹
Ospedale Cà Granda - Niguarda S.C: Ematologia, Milano, Italy
Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT03671564
- Locations
- 🇯🇵
Japanese Red Cross Narita Hospital, Chiba, Japan
🇯🇵Kyusyu University Hospital, Fukuoka, Japan
🇯🇵Gifu Municipal Hospital, Gifu, Japan
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
Phase 2
Recruiting
- Conditions
- Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaRecurrent Acute Myeloid Leukemia
- Interventions
- Drug: Liposome-encapsulated Daunorubicin-CytarabineOther: Quality-of-Life Assessment
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03672539
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 61
- Registration Number
- NCT03625505
- Locations
- 🇺🇸
David Geffen School of Medicin /ID# 200166, Los Angeles, California, United States
🇺🇸UC San Francisco Medical Center-Parnassus /ID# 200205, San Francisco, California, United States
🇺🇸Sylvester Comprehensive Cancer /ID# 200268, Miami, Florida, United States
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Phase 2
Terminated
- Conditions
- Non-Hodgkin LymphomaChronic Lymphocytic LeukemiaAcute Lymphoid Leukemia (ALL)Chronic Myeloid Leukemia (CML)Hodgkin LymphomaAcute Myeloid Leukemia (AML)
- Interventions
- Radiation: Hyperfractionated total body irradiationProcedure: HPC(A) stem cell allograftDevice: Rabbit antithymocyte globulin
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT03615105
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT03614728
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Phase 1
Active, not recruiting
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable)Hematopoietic Stem Cell Transplant
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Jacqueline Garcia, MD
- Target Recruit Count
- 102
- Registration Number
- NCT03613532
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 120
- Registration Number
- NCT03609060
- Locations
- 🇫🇷
CHU ANGERS - Maladies du sang, Angers, France
🇫🇷Ch Avignon, Avignon, France
🇫🇷CH de la Côte Basque - Hématologie, Bayonne, France
Atovaquone (Mepron®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML)
Early Phase 1
Active, not recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 26
- Registration Number
- NCT03568994
- Locations
- 🇺🇸
Johns Hopkins Medicine, Baltimore, Maryland, United States
🇺🇸Baylor College of Medicine - Texas Childrens Hospital, Houston, Texas, United States